Gilead Gets FDA Approval for New Cancer Therapy

Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.

Provided by EUPB - Read the full story at the source site.
Read The Full Story

Top News